ID   SPTC1_HUMAN             Reviewed;         473 AA.
AC   O15269; A8K681; Q5VWB4; Q96IX6;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   28-JUN-2023, entry version 206.
DE   RecName: Full=Serine palmitoyltransferase 1;
DE            EC=2.3.1.50 {ECO:0000269|PubMed:19416851};
DE   AltName: Full=Long chain base biosynthesis protein 1;
DE            Short=LCB 1;
DE   AltName: Full=Serine-palmitoyl-CoA transferase 1;
DE            Short=SPT 1;
DE            Short=SPT1;
GN   Name=SPTLC1; Synonyms=LCB1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Kidney;
RX   PubMed=9363775; DOI=10.1111/j.1432-1033.1997.00239.x;
RA   Weiss B., Stoffel W.;
RT   "Human and murine serine-palmitoyl-CoA transferase. Cloning, expression and
RT   characterization of the key enzyme in sphingolipid synthesis.";
RL   Eur. J. Biochem. 249:239-247(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANTS HSAN1A
RP   TRP-133; TYR-133 AND ASP-144.
RX   PubMed=11242114; DOI=10.1038/85879;
RA   Dawkins J.L., Hulme D.J., Brahmbhatt S.B., Auer-Grumbach M.,
RA   Nicholson G.A.;
RT   "Mutations in SPTLC1, encoding serine palmitoyltransferase, long chain base
RT   subunit-1, cause hereditary sensory neuropathy type I.";
RL   Nat. Genet. 27:309-312(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   TISSUE SPECIFICITY.
RX   PubMed=17023427; DOI=10.1074/jbc.m608066200;
RA   Hornemann T., Richard S., Ruetti M.F., Wei Y., von Eckardstein A.;
RT   "Cloning and initial characterization of a new subunit for mammalian
RT   serine-palmitoyltransferase.";
RL   J. Biol. Chem. 281:37275-37281(2006).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, IDENTIFICATION IN THE SPT COMPLEX, AND
RP   INTERACTION WITH SPTSSA AND SPTSSB.
RX   PubMed=19416851; DOI=10.1073/pnas.0811269106;
RA   Han G., Gupta S.D., Gable K., Niranjanakumari S., Moitra P., Eichler F.,
RA   Brown R.H. Jr., Harmon J.M., Dunn T.M.;
RT   "Identification of small subunits of mammalian serine palmitoyltransferase
RT   that confer distinct acyl-CoA substrate specificities.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:8186-8191(2009).
RN   [9]
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND CHARACTERIZATION OF VARIANT HSAN1A
RP   TRP-133.
RX   PubMed=20504773; DOI=10.1074/jbc.m110.122259;
RA   Gable K., Gupta S.D., Han G., Niranjanakumari S., Harmon J.M., Dunn T.M.;
RT   "A disease-causing mutation in the active site of serine
RT   palmitoyltransferase causes catalytic promiscuity.";
RL   J. Biol. Chem. 285:22846-22852(2010).
RN   [10]
RP   INTERACTION WITH ORMDL3.
RX   PubMed=20182505; DOI=10.1038/nature08787;
RA   Breslow D.K., Collins S.R., Bodenmiller B., Aebersold R., Simons K.,
RA   Shevchenko A., Ejsing C.S., Weissman J.S.;
RT   "Orm family proteins mediate sphingolipid homeostasis.";
RL   Nature 463:1048-1053(2010).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   INDUCTION IN ALZHEIMER DISEASE.
RX   PubMed=21994399; DOI=10.1523/jneurosci.3883-11.2011;
RA   Geekiyanage H., Chan C.;
RT   "MicroRNA-137/181c regulates serine palmitoyltransferase and in turn
RT   amyloid beta, novel targets in sporadic Alzheimer's disease.";
RL   J. Neurosci. 31:14820-14830(2011).
RN   [13]
RP   PHOSPHORYLATION AT TYR-164, AND MUTAGENESIS OF TYR-164.
RX   PubMed=23629659; DOI=10.1074/jbc.m112.409185;
RA   Taouji S., Higa A., Delom F., Palcy S., Mahon F.X., Pasquet J.M., Bosse R.,
RA   Segui B., Chevet E.;
RT   "Phosphorylation of serine palmitoyltransferase long chain-1 (SPTLC1) on
RT   tyrosine 164 inhibits its activity and promotes cell survival.";
RL   J. Biol. Chem. 288:17190-17201(2013).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [15]
RP   VARIANT ALA-387.
RX   PubMed=15037712; DOI=10.1212/01.wnl.0000115388.10828.5c;
RA   Verhoeven K., Coen K., De Vriendt E., Jacobs A., Van Gerwen V., Smouts I.,
RA   Pou-Serradell A., Martin J.-J., Timmerman V., De Jonghe P.;
RT   "SPTLC1 mutation in twin sisters with hereditary sensory neuropathy type
RT   I.";
RL   Neurology 62:1001-1002(2004).
RN   [16]
RP   VARIANT LEU-151.
RX   PubMed=17060578; DOI=10.1212/01.wnl.0000240068.21499.f5;
RA   Meggouh F., Bienfait H.M.E., Weterman M.A.J., de Visser M., Baas F.;
RT   "Charcot-Marie-Tooth disease due to a de novo mutation of the RAB7 gene.";
RL   Neurology 67:1476-1478(2006).
RN   [17]
RP   VARIANT [LARGE SCALE ANALYSIS] TRP-239.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [18]
RP   VARIANTS HSAN1A PHE-331 AND VAL-352.
RX   PubMed=19651702; DOI=10.1093/brain/awp198;
RA   Rotthier A., Baets J., De Vriendt E., Jacobs A., Auer-Grumbach M., Levy N.,
RA   Bonello-Palot N., Kilic S.S., Weis J., Nascimento A., Swinkels M.,
RA   Kruyt M.C., Jordanova A., De Jonghe P., Timmerman V.;
RT   "Genes for hereditary sensory and autonomic neuropathies: a genotype-
RT   phenotype correlation.";
RL   Brain 132:2699-2711(2009).
RN   [19]
RP   CHARACTERIZATION OF VARIANTS HSAN1A TYR-133; TRP-133 AND ASP-144,
RP   CHARACTERIZATION OF VARIANT ALA-387, AND LACK OF ASSOCIATION OF VARIANT
RP   ALA-387 WITH HSAN1A.
RX   PubMed=19132419; DOI=10.1007/s10048-008-0168-7;
RA   Hornemann T., Penno A., Richard S., Nicholson G., van Dijk F.S.,
RA   Rotthier A., Timmerman V., von Eckardstein A.;
RT   "A systematic comparison of all mutations in hereditary sensory neuropathy
RT   type I (HSAN I) reveals that the G387A mutation is not disease
RT   associated.";
RL   Neurogenetics 10:135-143(2009).
RN   [20]
RP   VARIANT HSAN1A PHE-331, AND CHARACTERIZATION OF VARIANTS HSAN1A PHE-331 AND
RP   VAL-352.
RX   PubMed=21618344; DOI=10.1002/humu.21481;
RA   Rotthier A., Penno A., Rautenstrauss B., Auer-Grumbach M., Stettner G.M.,
RA   Asselbergh B., Van Hoof K., Sticht H., Levy N., Timmerman V., Hornemann T.,
RA   Janssens K.;
RT   "Characterization of two mutations in the SPTLC1 subunit of serine
RT   palmitoyltransferase associated with hereditary sensory and autonomic
RT   neuropathy type I.";
RL   Hum. Mutat. 32:E2211-E2225(2011).
RN   [21]
RP   VARIANT HSAN1A TRP-133, AND VARIANT GLY-310.
RX   PubMed=22302274; DOI=10.1007/s00415-011-6397-y;
RA   Davidson G.L., Murphy S.M., Polke J.M., Laura M., Salih M.A., Muntoni F.,
RA   Blake J., Brandner S., Davies N., Horvath R., Price S., Donaghy M.,
RA   Roberts M., Foulds N., Ramdharry G., Soler D., Lunn M.P., Manji H.,
RA   Davis M.B., Houlden H., Reilly M.M.;
RT   "Frequency of mutations in the genes associated with hereditary sensory and
RT   autonomic neuropathy in a UK cohort.";
RL   J. Neurol. 259:1673-1685(2012).
RN   [22]
RP   INVOLVEMENT IN HMSN, VARIANT TYR-331, AND CHARACTERIZATION OF VARIANT
RP   TYR-331.
RX   PubMed=23454272; DOI=10.1016/j.ejmg.2013.02.002;
RA   Auer-Grumbach M., Bode H., Pieber T.R., Schabhuettl M., Fischer D.,
RA   Seidl R., Graf E., Wieland T., Schuh R., Vacariu G., Grill F.,
RA   Timmerman V., Strom T.M., Hornemann T.;
RT   "Mutations at Ser331 in the HSN type I gene SPTLC1 are associated with a
RT   distinct syndromic phenotype.";
RL   Eur. J. Med. Genet. 56:266-269(2013).
RN   [23]
RP   VARIANT HSAN1A PHE-331.
RX   PubMed=24247255; DOI=10.3892/mmr.2013.1808;
RA   Suh B.C., Hong Y.B., Nakhro K., Nam S.H., Chung K.W., Choi B.O.;
RT   "Early-onset severe hereditary sensory and autonomic neuropathy type 1 with
RT   S331F SPTLC1 mutation.";
RL   Mol. Med. Report. 9:481-486(2014).
RN   [24]
RP   VARIANT HSAN1A ASP-144.
RX   PubMed=30420926; DOI=10.1155/2018/1898151;
RA   Ho K.W.D., Jerath N.U.;
RT   "V144D Mutation of SPTLC1 Can Present with Both Painful and Painless
RT   Phenotypes in Hereditary Sensory and Autonomic Neuropathies Type I.";
RL   Case Rep. Genet. 2018:1898151-1898151(2018).
CC   -!- FUNCTION: Serine palmitoyltransferase (SPT) (PubMed:19416851). The
CC       heterodimer formed with SPTLC2 or SPTLC3 constitutes the catalytic core
CC       (PubMed:19416851). The composition of the serine palmitoyltransferase
CC       (SPT) complex determines the substrate preference (PubMed:19416851).
CC       The SPTLC1-SPTLC2-SPTSSA complex shows a strong preference for C16-CoA
CC       substrate, while the SPTLC1-SPTLC3-SPTSSA isozyme uses both C14-CoA and
CC       C16-CoA as substrates, with a slight preference for C14-CoA
CC       (PubMed:19416851). The SPTLC1-SPTLC2-SPTSSB complex shows a strong
CC       preference for C18-CoA substrate, while the SPTLC1-SPTLC3-SPTSSB
CC       isozyme displays an ability to use a broader range of acyl-CoAs,
CC       without apparent preference (PubMed:19416851). Required for adipocyte
CC       cell viability and metabolic homeostasis (By similarity).
CC       {ECO:0000250|UniProtKB:O35704, ECO:0000269|PubMed:19416851}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H(+) + hexadecanoyl-CoA + L-serine = 3-oxosphinganine + CO2 +
CC         CoA; Xref=Rhea:RHEA:14761, ChEBI:CHEBI:15378, ChEBI:CHEBI:16526,
CC         ChEBI:CHEBI:33384, ChEBI:CHEBI:57287, ChEBI:CHEBI:57379,
CC         ChEBI:CHEBI:58299; EC=2.3.1.50;
CC         Evidence={ECO:0000269|PubMed:19416851};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:14762;
CC         Evidence={ECO:0000269|PubMed:19416851};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H(+) + L-serine + octadecanoyl-CoA = 3-oxoeicosasphinganine +
CC         CO2 + CoA; Xref=Rhea:RHEA:33683, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:16526, ChEBI:CHEBI:33384, ChEBI:CHEBI:57287,
CC         ChEBI:CHEBI:57394, ChEBI:CHEBI:65073;
CC         Evidence={ECO:0000269|PubMed:19416851};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:33684;
CC         Evidence={ECO:0000269|PubMed:19416851};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H(+) + L-serine + tetradecanoyl-CoA = 3-oxohexadecasphinganine
CC         + CO2 + CoA; Xref=Rhea:RHEA:35675, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:16526, ChEBI:CHEBI:33384, ChEBI:CHEBI:57287,
CC         ChEBI:CHEBI:57385, ChEBI:CHEBI:71007;
CC         Evidence={ECO:0000269|PubMed:19416851};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:35676;
CC         Evidence={ECO:0000269|PubMed:19416851};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=dodecanoyl-CoA + H(+) + L-serine = 3-oxotetradecasphinganine +
CC         CO2 + CoA; Xref=Rhea:RHEA:35679, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:16526, ChEBI:CHEBI:33384, ChEBI:CHEBI:57287,
CC         ChEBI:CHEBI:57375, ChEBI:CHEBI:71008;
CC         Evidence={ECO:0000269|PubMed:19416851};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:35680;
CC         Evidence={ECO:0000269|PubMed:19416851};
CC   -!- COFACTOR:
CC       Name=pyridoxal 5'-phosphate; Xref=ChEBI:CHEBI:597326;
CC         Evidence={ECO:0000250};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.75 mM for serine {ECO:0000269|PubMed:20504773};
CC         Vmax=1350 pmol/min/mg enzyme {ECO:0000269|PubMed:20504773};
CC   -!- PATHWAY: Lipid metabolism; sphingolipid metabolism.
CC       {ECO:0000269|PubMed:19416851}.
CC   -!- SUBUNIT: Heterodimer with SPTLC2 or SPTLC3. Component of the serine
CC       palmitoyltransferase (SPT) complex, composed of SPTLC1, either SPTLC2
CC       or SPTLC3, and either SPTSSA or SPTSSB. The composition of the complex
CC       will define the substrate specificity. Interacts with SPTSSA and
CC       SPTSSB; the interaction is direct (PubMed:19416851). Interacts with
CC       ORMDL3 (PubMed:20182505). Interacts with RTN4 (isoform B) (By
CC       similarity). {ECO:0000250|UniProtKB:O35704,
CC       ECO:0000269|PubMed:19416851, ECO:0000269|PubMed:20182505}.
CC   -!- INTERACTION:
CC       O15269; Q8N138: ORMDL3; NbExp=3; IntAct=EBI-1044323, EBI-721750;
CC       O15269; Q9NUV7: SPTLC3; NbExp=3; IntAct=EBI-1044323, EBI-11614219;
CC       O15269-2; Q86SG2: ANKRD23; NbExp=3; IntAct=EBI-25912901, EBI-5661893;
CC       O15269-2; Q6ZR37: PLEKHG7; NbExp=3; IntAct=EBI-25912901, EBI-12891828;
CC       O15269-2; Q8IYM2: SLFN12; NbExp=3; IntAct=EBI-25912901, EBI-2822550;
CC       O15269-2; Q8WXH5: SOCS4; NbExp=3; IntAct=EBI-25912901, EBI-3942425;
CC       O15269-2; Q9UNE7: STUB1; NbExp=3; IntAct=EBI-25912901, EBI-357085;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000250|UniProtKB:O35704}; Single-pass membrane protein
CC       {ECO:0000250|UniProtKB:O35704}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O15269-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O15269-2; Sequence=VSP_043127, VSP_043128;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Not detected in small intestine.
CC       {ECO:0000269|PubMed:17023427}.
CC   -!- INDUCTION: Expression at protein level is highly increased in brains of
CC       patients with Alzheimer disease. No changes are observed at mRNA level.
CC       {ECO:0000269|PubMed:21994399}.
CC   -!- PTM: Phosphorylation at Tyr-164 inhibits activity and promotes cell
CC       survival. {ECO:0000269|PubMed:23629659}.
CC   -!- DISEASE: Neuropathy, hereditary sensory and autonomic, 1A (HSAN1A)
CC       [MIM:162400]: A form of hereditary sensory and autonomic neuropathy, a
CC       genetically and clinically heterogeneous group of disorders
CC       characterized by degeneration of dorsal root and autonomic ganglion
CC       cells, and by prominent sensory abnormalities with a variable degree of
CC       motor and autonomic dysfunction. The neurological phenotype is often
CC       complicated by severe infections, osteomyelitis, and amputations.
CC       HSAN1A is an autosomal dominant axonal form with onset in the second or
CC       third decades. Initial symptoms are loss of pain, touch, heat, and cold
CC       sensation over the feet, followed by distal muscle wasting and
CC       weakness. Loss of pain sensation leads to chronic skin ulcers and
CC       distal amputations. {ECO:0000269|PubMed:11242114,
CC       ECO:0000269|PubMed:19132419, ECO:0000269|PubMed:19651702,
CC       ECO:0000269|PubMed:20504773, ECO:0000269|PubMed:21618344,
CC       ECO:0000269|PubMed:22302274, ECO:0000269|PubMed:24247255,
CC       ECO:0000269|PubMed:30420926}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Note=SPTLC1 variants at Ser-331 are responsible for severe
CC       hereditary motor and sensory neuropathy (HMSN) forms, whose core
CC       features are severe, diffuse muscle wasting and hypotonia, motor and
CC       sensory disturbances, foot ulcers, amputations and/or burns, joint
CC       hypermobility, cataracts and considerable growth retardation.
CC       {ECO:0000269|PubMed:23454272}.
CC   -!- SIMILARITY: Belongs to the class-II pyridoxal-phosphate-dependent
CC       aminotransferase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Y08685; CAA69941.1; -; mRNA.
DR   EMBL; AF286717; AAK29328.1; -; Genomic_DNA.
DR   EMBL; AF286703; AAK29328.1; JOINED; Genomic_DNA.
DR   EMBL; AF286704; AAK29328.1; JOINED; Genomic_DNA.
DR   EMBL; AF286705; AAK29328.1; JOINED; Genomic_DNA.
DR   EMBL; AF286706; AAK29328.1; JOINED; Genomic_DNA.
DR   EMBL; AF286707; AAK29328.1; JOINED; Genomic_DNA.
DR   EMBL; AF286708; AAK29328.1; JOINED; Genomic_DNA.
DR   EMBL; AF286709; AAK29328.1; JOINED; Genomic_DNA.
DR   EMBL; AF286710; AAK29328.1; JOINED; Genomic_DNA.
DR   EMBL; AF286711; AAK29328.1; JOINED; Genomic_DNA.
DR   EMBL; AF286712; AAK29328.1; JOINED; Genomic_DNA.
DR   EMBL; AF286713; AAK29328.1; JOINED; Genomic_DNA.
DR   EMBL; AF286714; AAK29328.1; JOINED; Genomic_DNA.
DR   EMBL; AF286715; AAK29328.1; JOINED; Genomic_DNA.
DR   EMBL; AF286716; AAK29328.1; JOINED; Genomic_DNA.
DR   EMBL; AK291546; BAF84235.1; -; mRNA.
DR   EMBL; AL391219; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL354751; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471089; EAW62804.1; -; Genomic_DNA.
DR   EMBL; BC007085; AAH07085.1; -; mRNA.
DR   CCDS; CCDS6692.1; -. [O15269-1]
DR   CCDS; CCDS6693.1; -. [O15269-2]
DR   RefSeq; NP_001268232.1; NM_001281303.1.
DR   RefSeq; NP_006406.1; NM_006415.3. [O15269-1]
DR   RefSeq; NP_847894.1; NM_178324.2. [O15269-2]
DR   PDB; 6M4N; EM; 3.80 A; A/E=1-473.
DR   PDB; 6M4O; EM; 3.40 A; B/S=1-473.
DR   PDB; 7CQI; EM; 3.20 A; C/S=1-473.
DR   PDB; 7CQK; EM; 3.30 A; C/S=1-473.
DR   PDB; 7K0I; EM; 3.30 A; A/D=1-473.
DR   PDB; 7K0J; EM; 3.10 A; A=1-473.
DR   PDB; 7K0K; EM; 2.60 A; A=1-473.
DR   PDB; 7K0L; EM; 3.40 A; A=1-473.
DR   PDB; 7K0M; EM; 2.90 A; A/E=1-473.
DR   PDB; 7K0N; EM; 3.10 A; A/E=1-473.
DR   PDB; 7K0O; EM; 3.10 A; A/E=1-473.
DR   PDB; 7K0P; EM; 3.10 A; A/E=1-473.
DR   PDB; 7K0Q; EM; 3.30 A; A=1-473.
DR   PDBsum; 6M4N; -.
DR   PDBsum; 6M4O; -.
DR   PDBsum; 7CQI; -.
DR   PDBsum; 7CQK; -.
DR   PDBsum; 7K0I; -.
DR   PDBsum; 7K0J; -.
DR   PDBsum; 7K0K; -.
DR   PDBsum; 7K0L; -.
DR   PDBsum; 7K0M; -.
DR   PDBsum; 7K0N; -.
DR   PDBsum; 7K0O; -.
DR   PDBsum; 7K0P; -.
DR   PDBsum; 7K0Q; -.
DR   AlphaFoldDB; O15269; -.
DR   SMR; O15269; -.
DR   BioGRID; 115809; 162.
DR   ComplexPortal; CPX-6663; Serine palmitoyltransferase complex, SPTLC1-SPTLC2-SPTSSA variant.
DR   ComplexPortal; CPX-6664; Serine palmitoyltransferase complex, SPTLC1-SPTLC2-SPTSSB variant.
DR   ComplexPortal; CPX-6665; Serine palmitoyltransferase complex, SPTLC1-SPTLC3-SPTSSA variant.
DR   ComplexPortal; CPX-6681; Serine palmitoyltransferase complex, SPTLC1-SPTLC3-SPTSSB variant.
DR   CORUM; O15269; -.
DR   DIP; DIP-45626N; -.
DR   IntAct; O15269; 84.
DR   MINT; O15269; -.
DR   STRING; 9606.ENSP00000262554; -.
DR   BindingDB; O15269; -.
DR   ChEMBL; CHEMBL1250343; -.
DR   DrugBank; DB00114; Pyridoxal phosphate.
DR   DrugBank; DB00133; Serine.
DR   iPTMnet; O15269; -.
DR   MetOSite; O15269; -.
DR   PhosphoSitePlus; O15269; -.
DR   SwissPalm; O15269; -.
DR   BioMuta; SPTLC1; -.
DR   EPD; O15269; -.
DR   jPOST; O15269; -.
DR   MassIVE; O15269; -.
DR   MaxQB; O15269; -.
DR   PaxDb; O15269; -.
DR   PeptideAtlas; O15269; -.
DR   ProteomicsDB; 48557; -. [O15269-1]
DR   ProteomicsDB; 48558; -. [O15269-2]
DR   Antibodypedia; 2269; 425 antibodies from 37 providers.
DR   DNASU; 10558; -.
DR   Ensembl; ENST00000262554.7; ENSP00000262554.2; ENSG00000090054.16. [O15269-1]
DR   Ensembl; ENST00000337841.4; ENSP00000337635.4; ENSG00000090054.16. [O15269-2]
DR   Ensembl; ENST00000690139.1; ENSP00000510483.1; ENSG00000090054.16. [O15269-2]
DR   GeneID; 10558; -.
DR   KEGG; hsa:10558; -.
DR   MANE-Select; ENST00000262554.7; ENSP00000262554.2; NM_006415.4; NP_006406.1.
DR   UCSC; uc004arl.3; human. [O15269-1]
DR   AGR; HGNC:11277; -.
DR   CTD; 10558; -.
DR   DisGeNET; 10558; -.
DR   GeneCards; SPTLC1; -.
DR   GeneReviews; SPTLC1; -.
DR   HGNC; HGNC:11277; SPTLC1.
DR   HPA; ENSG00000090054; Low tissue specificity.
DR   MalaCards; SPTLC1; -.
DR   MIM; 162400; phenotype.
DR   MIM; 605712; gene.
DR   neXtProt; NX_O15269; -.
DR   OpenTargets; ENSG00000090054; -.
DR   Orphanet; 36386; Hereditary sensory and autonomic neuropathy type 1.
DR   Orphanet; 300605; Juvenile amyotrophic lateral sclerosis.
DR   PharmGKB; PA36106; -.
DR   VEuPathDB; HostDB:ENSG00000090054; -.
DR   eggNOG; KOG1358; Eukaryota.
DR   GeneTree; ENSGT00550000074872; -.
DR   HOGENOM; CLU_015846_0_1_1; -.
DR   InParanoid; O15269; -.
DR   OMA; GTIDTHE; -.
DR   OrthoDB; 9643at2759; -.
DR   PhylomeDB; O15269; -.
DR   TreeFam; TF314877; -.
DR   BioCyc; MetaCyc:HS01673-MON; -.
DR   BRENDA; 2.3.1.50; 2681.
DR   PathwayCommons; O15269; -.
DR   Reactome; R-HSA-1660661; Sphingolipid de novo biosynthesis.
DR   SABIO-RK; O15269; -.
DR   SignaLink; O15269; -.
DR   SIGNOR; O15269; -.
DR   UniPathway; UPA00222; -.
DR   BioGRID-ORCS; 10558; 265 hits in 1179 CRISPR screens.
DR   ChiTaRS; SPTLC1; human.
DR   GeneWiki; SPTLC1; -.
DR   GenomeRNAi; 10558; -.
DR   Pharos; O15269; Tchem.
DR   PRO; PR:O15269; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; O15269; protein.
DR   Bgee; ENSG00000090054; Expressed in esophagus squamous epithelium and 208 other tissues.
DR   ExpressionAtlas; O15269; baseline and differential.
DR   Genevisible; O15269; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0017059; C:serine C-palmitoyltransferase complex; IDA:UniProtKB.
DR   GO; GO:0035339; C:SPOTS complex; IDA:UniProtKB.
DR   GO; GO:0030170; F:pyridoxal phosphate binding; IEA:InterPro.
DR   GO; GO:0004758; F:serine C-palmitoyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0046513; P:ceramide biosynthetic process; IDA:MGI.
DR   GO; GO:1904504; P:positive regulation of lipophagy; IDA:MGI.
DR   GO; GO:1904649; P:regulation of fat cell apoptotic process; ISS:UniProtKB.
DR   GO; GO:0046511; P:sphinganine biosynthetic process; IEA:Ensembl.
DR   GO; GO:0030148; P:sphingolipid biosynthetic process; IDA:MGI.
DR   GO; GO:0006665; P:sphingolipid metabolic process; TAS:ProtInc.
DR   GO; GO:0006686; P:sphingomyelin biosynthetic process; IEA:Ensembl.
DR   GO; GO:0046512; P:sphingosine biosynthetic process; IDA:ComplexPortal.
DR   Gene3D; 3.90.1150.10; Aspartate Aminotransferase, domain 1; 1.
DR   Gene3D; 3.40.640.10; Type I PLP-dependent aspartate aminotransferase-like (Major domain); 1.
DR   InterPro; IPR004839; Aminotransferase_I/II.
DR   InterPro; IPR015424; PyrdxlP-dep_Trfase.
DR   InterPro; IPR015421; PyrdxlP-dep_Trfase_major.
DR   InterPro; IPR015422; PyrdxlP-dep_Trfase_small.
DR   PANTHER; PTHR13693; CLASS II AMINOTRANSFERASE/8-AMINO-7-OXONONANOATE SYNTHASE; 1.
DR   PANTHER; PTHR13693:SF2; SERINE PALMITOYLTRANSFERASE 1; 1.
DR   Pfam; PF00155; Aminotran_1_2; 1.
DR   SUPFAM; SSF53383; PLP-dependent transferases; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acyltransferase; Alternative splicing; Disease variant;
KW   Endoplasmic reticulum; Lipid metabolism; Membrane; Neurodegeneration;
KW   Neuropathy; Phosphoprotein; Pyridoxal phosphate; Reference proteome;
KW   Sphingolipid metabolism; Transferase; Transmembrane; Transmembrane helix.
FT   CHAIN           1..473
FT                   /note="Serine palmitoyltransferase 1"
FT                   /id="PRO_0000163853"
FT   TOPO_DOM        1..15
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        16..36
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        37..473
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         164
FT                   /note="Phosphotyrosine; by ABL"
FT                   /evidence="ECO:0000269|PubMed:23629659"
FT   VAR_SEQ         143
FT                   /note="D -> E (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_043127"
FT   VAR_SEQ         144..473
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_043128"
FT   VARIANT         133
FT                   /note="C -> W (in HSAN1A; inactive in the heterodimeric SPT
FT                   complex; largely reduced activity with serine as substrate,
FT                   but nearly no effect on serine affinity in the
FT                   heterotrimeric SPT complex; in contrast to wild-type is
FT                   able to use alanine as substrate leading to the formation
FT                   of 1-deoxysphinganine (1-deoxySa); does not interfere with
FT                   SPT complex formation; dbSNP:rs119482082)"
FT                   /evidence="ECO:0000269|PubMed:11242114,
FT                   ECO:0000269|PubMed:19132419, ECO:0000269|PubMed:20504773,
FT                   ECO:0000269|PubMed:22302274"
FT                   /id="VAR_011392"
FT   VARIANT         133
FT                   /note="C -> Y (in HSAN1A; reduced activity; does not
FT                   interfere with SPT complex formation; dbSNP:rs119482081)"
FT                   /evidence="ECO:0000269|PubMed:11242114,
FT                   ECO:0000269|PubMed:19132419"
FT                   /id="VAR_011393"
FT   VARIANT         144
FT                   /note="V -> D (in HSAN1A; present with both painful and
FT                   painles phenotypes; reduced activity; does not interfere
FT                   with SPT complex formation; dbSNP:rs119482083)"
FT                   /evidence="ECO:0000269|PubMed:11242114,
FT                   ECO:0000269|PubMed:19132419, ECO:0000269|PubMed:30420926"
FT                   /id="VAR_011394"
FT   VARIANT         151
FT                   /note="R -> L (in dbSNP:rs45461899)"
FT                   /evidence="ECO:0000269|PubMed:17060578"
FT                   /id="VAR_037889"
FT   VARIANT         239
FT                   /note="R -> W (in a breast cancer sample; somatic mutation;
FT                   dbSNP:rs542876370)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036610"
FT   VARIANT         310
FT                   /note="A -> G (found in a patient with HSAN1A; uncertain
FT                   pathological significance; dbSNP:rs768841574)"
FT                   /evidence="ECO:0000269|PubMed:22302274"
FT                   /id="VAR_068476"
FT   VARIANT         331
FT                   /note="S -> F (in HSAN1A; severe form with early onset;
FT                   reduced activity; dbSNP:rs267607087)"
FT                   /evidence="ECO:0000269|PubMed:19651702,
FT                   ECO:0000269|PubMed:21618344, ECO:0000269|PubMed:24247255"
FT                   /id="VAR_066245"
FT   VARIANT         331
FT                   /note="S -> Y (probable disease-associated variant found in
FT                   severe HMSN; reduced activity; dbSNP:rs267607087)"
FT                   /evidence="ECO:0000269|PubMed:23454272"
FT                   /id="VAR_073294"
FT   VARIANT         352
FT                   /note="A -> V (in HSAN1A; reduced activity;
FT                   dbSNP:rs267607088)"
FT                   /evidence="ECO:0000269|PubMed:19651702,
FT                   ECO:0000269|PubMed:21618344"
FT                   /id="VAR_066246"
FT   VARIANT         387
FT                   /note="G -> A (does not affect activity; does not interfere
FT                   with SPT complex formation; dbSNP:rs119482084)"
FT                   /evidence="ECO:0000269|PubMed:15037712,
FT                   ECO:0000269|PubMed:19132419"
FT                   /id="VAR_037890"
FT   MUTAGEN         164
FT                   /note="Y->F: Increased serine palmitoyltransferase activity
FT                   and sphingolipid content."
FT                   /evidence="ECO:0000269|PubMed:23629659"
FT   HELIX           11..18
FT                   /evidence="ECO:0007829|PDB:7K0M"
FT   HELIX           22..39
FT                   /evidence="ECO:0007829|PDB:7K0M"
FT   HELIX           54..63
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   HELIX           78..80
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   STRAND          85..87
FT                   /evidence="ECO:0007829|PDB:7K0M"
FT   STRAND          91..95
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   STRAND          98..102
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   STRAND          108..110
FT                   /evidence="ECO:0007829|PDB:7K0J"
FT   HELIX           115..128
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   TURN            136..139
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   HELIX           143..155
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   STRAND          159..166
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   HELIX           167..178
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   STRAND          184..188
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   HELIX           193..201
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   STRAND          205..209
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   HELIX           214..230
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   HELIX           232..237
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   STRAND          240..247
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   TURN            249..251
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   HELIX           257..267
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   STRAND          270..274
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   TURN            276..281
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   STRAND          282..286
FT                   /evidence="ECO:0007829|PDB:7K0M"
FT   HELIX           289..293
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   HELIX           297..299
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   STRAND          301..306
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   STRAND          309..311
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   STRAND          316..320
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   HELIX           322..331
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   HELIX           333..336
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   HELIX           343..358
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   HELIX           362..377
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   STRAND          381..387
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   STRAND          392..400
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   HELIX           405..420
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   TURN            421..423
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   TURN            433..435
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   STRAND          436..438
FT                   /evidence="ECO:0007829|PDB:6M4O"
FT   STRAND          443..447
FT                   /evidence="ECO:0007829|PDB:7K0K"
FT   STRAND          450..452
FT                   /evidence="ECO:0007829|PDB:7K0N"
FT   HELIX           454..471
FT                   /evidence="ECO:0007829|PDB:7K0K"
SQ   SEQUENCE   473 AA;  52744 MW;  BA9E056A869D2EA2 CRC64;
     MATATEQWVL VEMVQALYEA PAYHLILEGI LILWIIRLLF SKTYKLQERS DLTVKEKEEL
     IEEWQPEPLV PPVPKDHPAL NYNIVSGPPS HKTVVNGKEC INFASFNFLG LLDNPRVKAA
     ALASLKKYGV GTCGPRGFYG TFDVHLDLED RLAKFMKTEE AIIYSYGFAT IASAIPAYSK
     RGDIVFVDRA ACFAIQKGLQ ASRSDIKLFK HNDMADLERL LKEQEIEDQK NPRKARVTRR
     FIVVEGLYMN TGTICPLPEL VKLKYKYKAR IFLEESLSFG VLGEHGRGVT EHYGINIDDI
     DLISANMENA LASIGGFCCG RSFVIDHQRL SGQGYCFSAS LPPLLAAAAI EALNIMEENP
     GIFAVLKEKC GQIHKALQGI SGLKVVGESL SPAFHLQLEE STGSREQDVR LLQEIVDQCM
     NRSIALTQAR YLEKEEKCLP PPSIRVVVTV EQTEEELERA ASTIKEVAQA VLL
//
